Modafinil for social phobia and amphetamine dependence [2]

American Journal of Psychiatry

Volumn 159, Issue 11, 2002, Pages 1947-1948

  Camacho, Alvaro ^a   Stein, Murray B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTICONVULSIVE AGENT; DEXAMPHETAMINE; FLUOXETINE; LITHIUM; METHYLPHENIDATE; MODAFINIL; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; CASE REPORT; CLINICAL EXAMINATION; DRUG DEPENDENCE; DRUG MISUSE; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; SOCIAL PHOBIA; WITHDRAWAL SYNDROME;

AMPHETAMINE-RELATED DISORDERS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MIDDLE AGED; PHOBIC DISORDERS; REHABILITATION, VOCATIONAL;

EID: 0036843811     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.11.1947     Document Type: Letter

References (5)

1. Marlatt GA, Tucker JA, Donovan DM, Vuchinich RE: Help-seeking by substance abusers: The role of harm reduction and behavioral-economic approaches to facilitate treatment entry and retention. NIDA Res Monogr 1997; 165:44-84
2. Engber TM, Dennis SA, Jones BE, Miller MS, Contreras PC: Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: Comparison with amphetamine. Neuroscience 1998; 87:905-911
3. Simon P, Panissaud C, Costentin J: The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice: a comparison with dexamphetamine. Psychopharmacology (Berl) 1994; 114:597-600
4. 2 receptor binding potential in social phobia. Am J Psychiatry 2000; 157:457-459
5. Community Epidemiology Work Group: Epidemiologic Trends in Drug Abuse, Highlights and Executive Summary, vol 1. Bethesda, Md, National Institute on Drug Abuse, 1998, pp 59-66